首页>
外文期刊>American journal of clinical dermatology
>These dermatological disorders share the features of being caused by hyperactivity of androgen within the pilosebaceous follicle, and although not life threatening are the source of a considerable psychological and emotional burden for patients. Foreword.
【24h】
These dermatological disorders share the features of being caused by hyperactivity of androgen within the pilosebaceous follicle, and although not life threatening are the source of a considerable psychological and emotional burden for patients. Foreword.
In this supplement to the American Journal of Clinical Dermatology the use of the combined oral contraceptive (OC) ethinylestradiol/chlormadinone acetate (EE/CMA) 0.03 mg/2mg in female patients with commonly seen disorders of the pilosebaceous unit (PSU): acne, female pattern hair loss (FPHL), hirsutism and seborrhea is discussed. These dermatological disorders share the features of being caused by hyperactivity of androgen within the pilosebaceous follicle, and although not life threatening are the source of a considerable psychological and emotional burden for patients. Approved in Europe as a contraceptive, EE/CMA 0.03 mg/2mg is also currently being evaluated as a treatment for acne. Some data also exist suggesting that EE/CMA may have a beneficial effect in patients with FPHL, hirsutism and seborrhea.
展开▼
